Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a Healthcare company (Biotechnology) with a market capitalization of $83M. The Maz Rating grades it against the other companies in its sector.
Black Diamond Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.44, Black Diamond Therapeutics, Inc. trades at 0.9x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -44.0%, return on invested capital of -51.0% and a free cash flow yield of -39.8%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 6.92. Over the past 52 weeks the share price ranged from $1.39 to $4.06, with a beta of 3.46.
Black Diamond Therapeutics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.